Please login to the form below
Lyxumia
This page shows the latest Lyxumia news and features for those working in and with pharma, biotech and healthcare.
Sanofi wins EU approval for new diabetes combination Suliqua
European Commission licenses the once-daily version of Lantus and Lyxumia. Sanofi's combination therapy Suliqua has been granted European marketing approval for the treatment of adults with type 2 diabetes. ... The dual-drug treatment combines the firm's
Latest news
-
Sanofi launches insulin combo Soliqua in US
Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy
-
FDA clears rival diabetes combos from Sanofi and Novo Nordisk
Adlyxin/Lyxumia (lixisenatide).
-
Gilead's hepatitis B virus treatment set for European approval
Sanofi's lixisenatide-only drug Lyxumia has been on the market in Europe since 2013 and was approved in the US by the FDA as Adlyxin in July this year.
-
Sanofi trumpets new IGlarLixi data after regulatory delay
Lyxumia (lixisenatide) - helped more patients with type 2 diabetes reach post-prandial glucose targets than Lantus.
-
Sanofi loses lead on diabetes combo IGlarLixi after FDA delay
Lyxumia (lixisenatide), and has extended its review period by three months.
More from news
Approximately 12 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
Suliqua &Lyxumia/ Adlyxin for Type 2 diabetes. Purchase of. royalty rights.
-
Interview: Pierre Chancel, Sanofi Diabetes
Key among these for Sanofi is Lyxumia (lixisenatide), the company's new GLP-1 receptor agonist, which is planned for first launch in Germany following European approval and has been accepted ... With a single daily injection and only one step to
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Roche’s Torsten Hoffmann to join Zealand Pharma
Its lead product is the GLP-1 agonist lixisenatide, which is licensed to Sanofi who markets it as Lyxumia for the treatment of type 2 diabetes.
-
Agneta Svedberg appointed COO at Zealand Pharma
The appointment comes at crucial time for Zealand, with its diabetes partnership with Sanofi set to pay off as the big pharma company gears up to launch Lyxumia (lixisenatide) this year.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- World Health Organization releases new road map for breast cancer
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Making new year resolutions that can also benefit others
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Bristol Myers Squibb’s plaque psoriasis treatment recommended by CHMP
- Europe’s cancer community publishes new report on transforming patient care
- Assessing the value of interim analyses in clinical trials
- Piloting a route to the biosimilars opportunities in Europe
- Pre-launch planning and DSLs – the new ways to create launch excellence in pharma
PMHub
BOLDSCIENCE
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
